Try GOLD - Free

Food delivery giants rid health wave to bulk ma

Mint Mumbai

|

October 02, 2025

Zomato and Swiggy are bringing in features like 'healthy mode' and a 'high

- Vaeshnavi Kasthuril & Sakshi Sadashiv

Food delivery giants rid health wave to bulk ma

Eternal rolled out 'Healthy Mode', a pilot feature that rates meals

(MINT)

Food delivery majors Zomato and Swiggy are betting big on the health wave—a push aimed at wooing India’s fitness-conscious diners while padding margins. The bet is driving premiumisation on their platforms and nudging average order values higher.

Eternal Ltd, earlier known as Zomato, on Monday rolled out ‘Healthy Mode’, a new pilot feature that rates meals on their nutritional value. The pilot feature is currently available only in Gurugram and will be expanded to other cities in the coming months. The launch comes at a time when growth in the food delivery segment has begun to slow down.

According to a Goldman Sachs report on 1 September, Zomato’s food delivery net order value (NOV) growth is expected to moderate at around 18% in FY26, well below the triple-digit surge seen in Blinkit. This reflects a maturing market where user additions have slowed, making higher average order values a key lever for growth.

Analysts agree the move is timely. “The newer generation is moving towards healthy foods, so I think this is a great move. But still, whether premiumisation will really happen remains to be seen,” said Sandeep Abhange, research analyst, Consumer and Midcaps at LKP Securities.

MORE STORIES FROM Mint Mumbai

Mint Mumbai

Mint Mumbai

Gen Alpha will make new rules for their workplace

Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’

time to read

3 mins

December 01, 2025

Mint Mumbai

EC extends electoral roll revision by a week to II Dec; final list on 14 Feb

The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.

time to read

2 mins

December 01, 2025

Mint Mumbai

THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS

These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.

time to read

3 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

Green hydrogen: Fast fashion could help bump up demand

A boom in its use for clean synthetic inputs might make a difference

time to read

3 mins

December 01, 2025

Mint Mumbai

Let's be a bit more selective in using the word 'reforms'

Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.

time to read

3 mins

December 01, 2025

Mint Mumbai

As mid-cap alpha shrinks, should you consider passive strategies?

Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey

time to read

4 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

With $2.2 bn fund, ChrysCap has appetite for riskier bets

MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing

time to read

3 mins

December 01, 2025

Mint Mumbai

GDP growth of 8% plus: How to sustain this pace

Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships

time to read

2 mins

December 01, 2025

Mint Mumbai

INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES

Detection tools today are not universal or consistent across languages

time to read

5 mins

December 01, 2025

Mint Mumbai

Mint Mumbai

APIs to innovation: Bulk drug makers ramp up CDMO bets

Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.

time to read

2 mins

December 01, 2025

Listen

Translate

Share

-
+

Change font size